Cyclerion Therapeutics (NASDAQ:KRSA) Now Covered by TD Cowen

Stock analysts at TD Cowen started coverage on shares of Cyclerion Therapeutics (NASDAQ:KRSA) in a research note issued to investors on Monday, Briefing.com reports. The firm set a “buy” rating on the stock.

Several other equities research analysts have also recently weighed in on KRSA. UBS Group initiated coverage on shares of Cyclerion Therapeutics in a research report on Friday. They set a “buy” rating and a $55.00 price objective for the company. Zacks Research raised shares of Cyclerion Therapeutics to a “hold” rating in a research note on Wednesday, September 9th. Finally, Stifel Nicolaus started coverage on Cyclerion Therapeutics in a research note on Monday. They set a “buy” rating and a $43.00 target price on the stock. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Cyclerion Therapeutics presently has a consensus rating of “Buy” and an average price target of $49.00.

Cyclerion Therapeutics Trading Down 3.5%

NASDAQ:KRSA traded down $1.12 on Monday, reaching $30.79. The company’s stock had a trading volume of 4,422 shares, compared to its average volume of 313,500. Cyclerion Therapeutics has a 1-year low of $7.19 and a 1-year high of $59.36. The stock has a market cap of $20.63 million, a price-to-earnings ratio of -2.65 and a beta of 1.75.

Cyclerion Therapeutics Company Profile

Cyclerion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing medicines for serious diseases of the central nervous system. The company has concentrated on therapies designed to influence the nitric oxide–soluble guanylate cyclase signaling pathway, which may play a role in neurological and other debilitating conditions.

Cyclerion’s lead development program was IW-6463, an oral, central nervous system-penetrant soluble guanylate cyclase stimulator investigated for potential use in neurodegenerative diseases, including Alzheimer’s disease and amyotrophic lateral sclerosis.